OTCPK:PURE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has PURE Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PURE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.9%

PURE

0.7%

US Household Products

-0.7%

US Market


1 Year Return

556.5%

PURE

23.2%

US Household Products

19.9%

US Market

Return vs Industry: PURE exceeded the US Household Products industry which returned 23.2% over the past year.

Return vs Market: PURE exceeded the US Market which returned 19.9% over the past year.


Shareholder returns

PUREIndustryMarket
7 Day4.9%0.7%-0.7%
30 Day-3.2%5.0%5.8%
90 Day23.8%12.1%8.3%
1 Year556.5%556.5%25.6%23.2%22.7%19.9%
3 Year33.6%33.6%64.8%52.7%43.5%33.9%
5 Year115.7%115.7%95.3%71.2%86.9%65.8%

Price Volatility Vs. Market

How volatile is PURE Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PURE Bioscience undervalued compared to its fair value and its price relative to the market?

31458.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PURE ($1.51) is trading above our estimate of fair value ($0.68)

Significantly Below Fair Value: PURE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PURE is poor value based on its PE Ratio (31458.3x) compared to the US Household Products industry average (25.4x).

PE vs Market: PURE is poor value based on its PE Ratio (31458.3x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PURE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PURE is overvalued based on its PB Ratio (27.3x) compared to the US Household Products industry average (7.4x).


Next Steps

Future Growth

How is PURE Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

5.8%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PURE Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PURE Bioscience performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PURE has high quality earnings.

Growing Profit Margin: PURE became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: PURE has become profitable over the past 5 years, growing earnings by 24.6% per year.

Accelerating Growth: PURE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PURE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Household Products industry (30.9%).


Return on Equity

High ROE: PURE's Return on Equity (0.08%) is considered low.


Next Steps

Financial Health

How is PURE Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: PURE's short term assets ($5.6M) exceed its short term liabilities ($1.5M).

Long Term Liabilities: PURE has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PURE is debt free.

Reducing Debt: PURE had no debt 5 years ago.

Debt Coverage: PURE has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PURE has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is PURE Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PURE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Tom Lee (71 yo)

1.17yrs

Tenure

US$288,000

Compensation

Mr. Tom Y. Lee, CPA, is Chief Executive Officer of PURE Bioscience, Inc. since August 7, 2019 and has been its President since July 25, 2019. He serves as the Chairman and Chief Executive Officer of Swabpl ...


Leadership Team

NamePositionTenureCompensationOwnership
Tom Lee
CEO, President & Chairman1.17yrsUS$288.00k25.14%
$ 33.0m
Mark Elliott
VP of Finance and Principal Financial & Accounting Officer5.25yrsUS$231.00k0.083%
$ 109.2k
Thomas Myers
Chief Operating Officer2yrsUS$535.00k0.37%
$ 483.3k
Bridget Tinsley-Cormier
Senior VP of Technology & Business Development and VP of Market Development4.17yrsno datano data

3.1yrs

Average Tenure

68yo

Average Age

Experienced Management: PURE's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tom Lee
CEO, President & Chairman1.17yrsUS$288.00k25.14%
$ 33.0m
Thomas Thompson
Member of Advisory Panel11.08yrsUS$10.58kno data
Scott Russell
Member of Advisory Panel11.08yrsno datano data
Thomas Ridge
Member of Advisory Panel11.08yrsno datano data
Dale Okuno
Independent Director1.75yrsUS$109.00k8.12%
$ 10.7m
James Marsden
Member of Scientific Advisory Board4.58yrsno datano data
Robert Deibel
Member of the Advisory Panel9.42yrsno datano data
Elisabeth Hagen
Member of Scientific Advisory Board1.75yrsUS$10.00kno data
Ivan Chen
Independent Director2.33yrsUS$126.00k0.52%
$ 679.5k

4.6yrs

Average Tenure

69.5yo

Average Age

Experienced Board: PURE's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.


Top Shareholders

Company Information

PURE Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PURE Bioscience, Inc.
  • Ticker: PURE
  • Exchange: OTCPK
  • Founded: 1992
  • Industry: Household Products
  • Sector: Household
  • Market Cap: US$131.480m
  • Shares outstanding: 87.07m
  • Website: https://www.purebio.com

Number of Employees


Location

  • PURE Bioscience, Inc.
  • 9669 Hermosa Avenue
  • Rancho Cucamonga
  • California
  • 91730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PUREOTCPK (Pink Sheets LLC)YesClass A Common StockUSUSDAug 1996
IVMBBST (Boerse-Stuttgart)YesClass A Common StockDEEURAug 1996

Biography

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/19 06:56
End of Day Share Price2020/10/16 00:00
Earnings2020/07/31
Annual Earnings2020/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.